文献速递真菌感染

系列氟脱氧葡萄糖正电子发射断层扫描-计算机断层扫描(18FDG-PET-CT)评估慢性肺曲霉病治疗反应

Serial Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (18FDG-PET-CT) in Assessing Treatment Response in Chronic Pulmonary Aspergillosis.
PubMed 文献 · J Infect Dis · 2025-01-01

研究比较口服伊曲康唑6个月后治疗成功与失败的慢性肺曲霉病患者FDG-PET/CT参数变化。94例患者基线及77例随访PET-CT,治疗成功43例、失败34例。完全代谢反应仅见于治疗成功者(18.6%),但19%治疗成功者出现进展性代谢病,PET-CT误判约五分之一参与者。

要点

  • 口服伊曲康唑6个月后,完全代谢反应仅见于治疗成功者(18.6%),治疗失败者无完全代谢反应。
  • 治疗成功者中更高比例达到部分代谢反应,但19%治疗成功者出现进展性代谢病。
  • 多数PET-CT参数随治疗改善,但PET-CT误判约五分之一参与者。

核心结论

  • 多数PET-CT参数随治疗改善,但PET-CT误判约五分之一参与者。

研究设计与样本

  • 在基线和口服伊曲康唑治疗6个月后行PET-CT,比较治疗成功与失败者的FDG-PET/CT参数。
  • 纳入94例慢性肺曲霉病患者(63例男性),平均年龄46.2岁,77例完成随访PET-CT。

主要发现

  • 治疗成功43例,治疗失败34例。
  • 完全代谢反应见于18.6%的治疗成功者,治疗失败者中无完全代谢反应。
  • 更高比例的治疗成功者达到部分代谢反应;19%的治疗成功者出现进展性代谢病。

关键数值与推荐

  • FDG摄取与背景相似或Z评分下降≥13单位定义为完全代谢反应。
  • SUVmax、SUVpeak和总糖酵解活性(TLG)分别下降>25%、>30%和>45%定义为部分代谢反应。
  • SUVmax、SUVpeak和TLG分别增加>30%、>30%或>75%定义为进展性代谢病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of 2-deoxy-2-18(F) fluoro-D-glucose (FDG) positron emission tomography (PET)-computed tomography (CT) in assessing treatment response in chronic pulmonary aspergillosis (CPA) remains to be determined. The study objective was to compare FDG-PET/CT parameters in persons with CPA achieving treatment success or failure after 6 months of oral itraconazole. METHODS: We performed PET-CT at baseline and after 6 months of oral itraconazole therapy. FDG uptake similar to the background uptake or ≥13 units decline in Z-score was considered a complete metabolic response (CMR). A >25%, >30%, and > 45% decline in standardised uptake value (SUVmax), SUVpeak, and total glycolytic activity (TLG) was labelled as a partial metabolic response (PMR). A >30%, >30%, or >75% increase in the SUVmax, SUVpeak, and TLG represented progressive metabolic disease. RESULTS: We included 94 persons with CPA (63 male) with a mean age of 46.2 years. A follow-up PET-CT was performed on 77 participants. We recorded treatment success and failure in 43 and 34 patients. CMR was seen in 18.6% of those with treatment success and none with treatment failure. A higher proportion of patients with treatment success achieved PMR; 19% of the patients with treatment success had progressive metabolic disease. CONCLUSIONS: Most PET-CT parameters improved with treatment; however, PET-CT misclassified one-fifth of the participants.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Sehgal IS, Arora K, Agarwal R, et al. Serial Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (18FDG-PET-CT) in Assessing Treatment Response in Chronic Pulmonary Aspergillosis. J Infect Dis. 2025. PMID: 39159179. doi:10.1093/infdis/jiae409

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。